Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100

Gene Therapy

Volumn 9, Issue 9, 2002, Pages 592-601

  Xia, D J ^a   Zhang, W P ^b   Zheng, S ^a   Wang, J ^a   Pan, J P ^a   Wang, Q ^a   Zhang, L H ^a   Hamada, H ^c   Cao, X ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antitumor immunity; Dendritic cells; Gene therapy; gp100; Lymphotactin

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA CHEMOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 2; LYMPHOTACTIN; MELANOMA ANTIGEN; TUMOR VACCINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; GENETIC TRANSFECTION; IMMUNIZATION; IN VIVO STUDY; INFLAMMATORY INFILTRATE; LYMPHOCYTE DEPLETION; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR NECROSIS; TUMOR REJECTION;

ANIMALS; CANCER VACCINES; CHEMOKINES, C; DENDRITIC CELLS; FEMALE; GENE THERAPY; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOKINES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; SIALOGLYCOPROTEINS; T-LYMPHOCYTES; TRANSFECTION;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0036262583     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301694     Document Type: Article

References (46)

1. Cancer vaccines in gene therapy
2. Cancer vaccines
3. Dendritic cells in cancer immunotherapy
4. Genetically engineered dendritic cell-based cancer vaccines
5. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
6. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
7. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transfected dendritic cells
8. Gene-modified dendritic cells for use in tumor vaccines
9. Gene-based cancer vaccines: An ex vivo approach
10. Dendritic cells and the control of immunity
11. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
12. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
13. A novel migration pathway for rat dendritic cells from the blood: Hepatic sinusoidslymph translocation
14. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone
15. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells
16. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells
17. Lymphotactin: A cytokine that respresents a new class of chemokine
18. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo
19. Lymphotactin
20. Migratory response of human natural killer cells to lymphotactin
21. Combined chemokine and cytokine gene transfer enhances antitumor immunity
22. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity
23. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12
24. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
25. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
26. Retroviral transfection of human dendritic cells with a tumor-associated antigen gene
27. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
28. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
29. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy
30. A comparison of gene transfer methods in human dendritic cells
31. Chemokines
32. Human chemokines: An update
33. Lymphotactin expression by engineered myeloma cells drives tumor regression: Mediated by CD4(+) and CD8(+) T cells and neutrophils expressing XCR1 receptor
34. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell sub-populations
35. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
36. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth
37. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy
38. + blood dendritic cells
39. Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3 alpha from lung dendritic cells
40. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin
41. The makings of a tumor rejection antigen
42. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100
43. gp100/pmel 17 is a murine tumor rejection antigen: Induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
44. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
45. The expanding universe of T-cell subsets: Th1, Th2 and more
46. Distinct role of antigen-specific T helper type (Th1) and Th2 cells in tumor eradication in vivo